Clinical-stage gene therapy company Genprex (NASDAQ: GNPX) on Monday provided a clinical, corporate and financial update for the year ended December 31, 2018. Among other highlights, Genprex reached various milestones in 2018 and early 2019 which included completing its initial public offering ("IPO") and listing of common stock on NASDAQ Capital Market, completing a $10 million private placement, and securing a contract with Accenture to provide clinical data management services to help fast-track the clinical development of Oncoprex(TM). "Over the past year, we made great progress in advancing the development of our gene therapy platform, including Oncoprex(TM) immunogene therapy for non-small cell lung cancer," Genprex Chairman and CEO Rodney Varner stated in the news release. "I'm pleased with our progress and am excited to continue development of our gene therapies for cancer into 2019 and beyond.